Douglas B Johnson (Satya Das)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 10

Top Topics

Drug Administration

Neuroendocrine Tumors

Radical Prostatectomy

Top Venues

Endocrine-related cancer

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Current oncology reports

This page only lists publications with an associated author ORCID identifier.

Publications

Isik Turker, Douglas B Johnson
Immune checkpoint Inhibitor-Related myocarditis: Current Understanding and potential diagnostic and therapeutic Strategies. Expert opinion on drug safety (2023)
Douglas B Johnson, Shannon S Stockton, Saamir A Hassan
Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration. The oncologist (2023)
Douglas B Johnson, Liping Du, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah, David Eisner, Dana Cardin, Kristen Ciombor, Laura Goff, Marques Bradshaw, Dominique Delbeke, Martin Sandler, Jordan Berlin
A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy. Endocrine-related cancer 28 (3) (2022)
Mintallah Haider, Douglas B Johnson, Taymeyah Al-Toubah, Eleonora Pelle, Ghassan El-Haddad, Jonathan R Strosberg
Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Endocrine-related cancer 28 (3) (2022)
Allison S Cohen, Joe Grudzinski, Gary T Smith, Todd E Peterson, Jennifer G Whisenant, Tiffany L Hickman, Kristen K Ciombor, Dana Cardin, Cathy Eng, Laura W Goff, Douglas B Johnson, D Borden Lacy, Jordan D Berlin, Henry Charles Manning
First-in-human PET imaging and estimated radiation dosimetry of L-[5-11C]-glutamine in patients with metastatic colorectal cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2021)
Douglas B Johnson, Arvind Dasari
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Current oncology reports 23 (4) (2021)
Douglas B Johnson, Arvind Dasari
Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Therapeutic advances in medical oncology 13 (2021)
Douglas B Johnson, Kristen K Ciombor, Sigurdis Haraldsdottir, Yoanna Pumpalova, Ibrahim H Sahin, G Pineda, Yu Shyr, E P Lin, Chih-Yuan Hsu, Shih-Kai Chu, Laura W Goff, Dana B Cardin, Mehmet A Bilen, George A Fisher, Christina Wu, Jordan Berlin
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. The oncologist 25 (8) (2020)
Douglas B Johnson, Sarah Cimino, Shemeka Davis, Kristen Ciombor
All in the Levels-Programmed Death-Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal Cancer. The oncologist 26 (1) (2020)
Douglas B Johnson, Douglas B Johnson
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. Journal for immunotherapy of cancer 7 (1) (2019)